Isomorphic Labs, a subsidiary of Alphabet Inc., has recently announced strategic research collaboration agreements with Novartis AG and Eli Lilly & Co. The partnerships aim to advance the development of small molecule therapeutics through the integration of artificial intelligence (AI), data science, and medicinal chemistry.
As part of the agreement with Eli Lilly, Isomorphic Labs will be granted an upfront cash payment of $45 million. The two companies will work together to research small molecule therapeutics for multiple targets. Moreover, Isomorphic Labs stands to earn up to $1.7 billion in performance-based milestone payments, excluding the initial payment and any subsequent tiered royalties on net sales.
Similarly, the collaboration with Novartis revolves around the discovery of small molecule therapeutics for three undisclosed targets. Isomorphic Labs will receive an upfront payment of $37.5 million and could potentially receive up to $1.2 billion in performance-based milestone payments.
By combining their respective expertise in AI, data science, medicinal chemistry, and disease area knowledge, Isomorphic Labs and its collaborators aim to unlock the potential of AI-driven drug discovery. This collaboration holds promise for advancing the field and opening up new possibilities for the development of innovative therapeutics.
Fiona Marshall, President of Biomedical Research at Novartis, expressed enthusiasm for the collaboration, stating, “This partnership brings together the unique strengths of our companies to drive advancements in AI-driven drug discovery.”
The integration of AI technology in the drug discovery process has the potential to revolutionize the industry. By leveraging AI algorithms and data analysis, researchers can identify potential drug candidates, predict their efficacy, and optimize their properties, streamlining the discovery and development timelines.
Through these partnerships, Isomorphic Labs aims to accelerate the pace of drug discovery and bring new treatments to patients faster. By harnessing the power of AI, they hope to unlock novel possibilities in the field of medicine and contribute to the advancement of healthcare as a whole.
The source of the article is from the blog girabetim.com.br